CRICO CRICO home

CRICO MDs ONLY: Register to access your facesheet, and more.

Recent Coverage

March 16, 2019 Bob Buckley: Get The Facts Straight On Medical Malpractice

Bob Buckley, an attorney in Independence, Missouri, touts the value of using the medical malpractice data and analysis featured in our recently published report, Medical Malpractice in America.

READ MORE >
March 15, 2019 Medical Malpractice Analysis in Radiation Oncology: A Decade of Results From a National Comparative Benchmarking System

Researchers used the CRICO Strategies’ national database of medical liability claims, Comparative Benchmarking System, to analyze the issue of medical errors in radiation oncology (RO).

READ MORE >
March 1, 2019 In Conversation With Susan Haas MD, MSc

Susan Haas, MD, MSc, of Ariadne Labs spoke with Medical Liability Monitor about Ariadne’s initiative which, in partnership and support from CRICO, addresses health care system expansion risks.

READ MORE >

View All News & Research

The Impact of Automated Notification on Follow-up of Actionable Tests Pending at Discharge: A Cluster-Randomized Controlled Trial

  • July 1, 2018

A physician’s failure to follow-up on test results that are still pending at a patient’s discharge (TPADs) could lead to a missed diagnosis or preventable adverse event. This CRICO-funded study researched whether automated notifications improved documented follow-up for tests that were actionable. 


The research concluded that automated notification of actionable TPADs did shorten the follow-up time by physicians for patients within their healthcare network.  However, the researchers noted that future research is needed to evaluate such safety concerns as “The high proportion of actionable TPADs without any documented follow-up (~ 40%).”

 

Citation for the Full-text Article

Dalal AK, Schaffer A, Gershanik EF,Papanna R, Eibensteiner K, Nolido NV, Yoon CS, Williams D, Lipsitz SR, Roy CL, Schnipper JL. The impact of automated notification on follow-up of actionable tests pending at discharge: a cluster-randomized controlled trial. July 2018, 33(7):1043–1051. DOI: 10.1007/s11606-018-4393-y